Susquehanna International Group
KYMR icon

Susquehanna International Group’s Kymera Therapeutics KYMR Stock Holding History

Susquehanna International Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.12M Buy
25,403
+19,503
+331% +$1.54M ﹤0.01% 6053
2025
Q4 		$459K Sell
5,900
-4,848
-45% -$327K ﹤0.01% 8992
2025
Q3 		$608K Sell
10,748
-46,708
-81% -$2.11M ﹤0.01% 8516
2025
Q2 		$2.51M Sell
57,456
-6,312
-10% -$217K ﹤0.01% 5322
2025
Q1 		$1.75M Buy
63,768
+33,358
+110% +$1.22M ﹤0.01% 5828
2024
Q4 		$1.22M Buy
30,410
+6,696
+28% +$302K ﹤0.01% 6468
2024
Q3 		$1.12M Buy
23,714
+5,922
+33% +$262K ﹤0.01% 6518
2024
Q2 		$531K Sell
17,792
-7,839
-31% -$271K ﹤0.01% 8130
2024
Q1 		$1.03M Sell
25,631
-4,646
-15% -$166K ﹤0.01% 6834
2023
Q4 		$771K Sell
30,277
-59,637
-66% -$1.07M ﹤0.01% 7628
2023
Q3 		$1.25M Sell
89,914
-5,342
-6% -$107K ﹤0.01% 6124
2023
Q2 		$2.19M Buy
95,256
+22,579
+31% +$647K ﹤0.01% 4966
2023
Q1 		$2.15M Buy
72,677
+55,867
+332% +$1.8M ﹤0.01% 4976
2022
Q4 		$420K Sell
16,810
-48,394
-74% -$1.29M ﹤0.01% 8301
2022
Q3 		$1.42M Buy
+65,204
New +$1.72M ﹤0.01% 5728
2022
Q2 		– Sell
-33,240
Closed -$1.41M – 13469
2022
Q1 		$1.41M Sell
33,240
-5,959
-15% -$252K ﹤0.01% 6297
2021
Q4 		$2.49M Buy
39,199
+14,895
+61% +$868K ﹤0.01% 5008
2021
Q3 		$1.43M Buy
24,304
+6,651
+38% +$386K ﹤0.01% 6617
2021
Q2 		$856K Sell
17,653
-20,776
-54% -$902K ﹤0.01% 8186
2021
Q1 		$1.49M Buy
+38,429
New +$2.31M ﹤0.01% 6650

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Susquehanna International Group's KYMR Position: Q1 2026 in Review

Susquehanna International Group increased its Kymera Therapeutics (KYMR) stake by 331% in Q1 2026, buying an estimated $1.54M and bringing the position to 25,403 shares worth $2.12M. The position accounts for ﹤0.01% of the portfolio, ranked #6053.

Susquehanna International Group first reported a position in KYMR in Q1 2021 and has held it in 20 quarters since. The position peaked at $2.51M in Q2 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Susquehanna International Group held 25,403 shares of Kymera Therapeutics worth $2.12M as of Q1 2026.
  • Susquehanna International Group bought 19,503 Kymera Therapeutics shares in Q1 2026, an estimated $1.54M.
  • Kymera Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6053 holding.
  • Susquehanna International Group first reported a position in Kymera Therapeutics in Q1 2021 and has held it in 20 quarters since.
  • Susquehanna International Group's Kymera Therapeutics position peaked at $2.51M in Q2 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.